Tag: ASEAN

Teledyne e2v’s Tetra Sensor

GRENOBLE, France, June 29, 2021 (GLOBE NEWSWIRE) — Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and part of the Teledyne Imaging group, introduces Tetra, a low-cost, high-performance quad linear CMOS sensor family. The Tetra sensors are ideal for food sorting, recycling, logistics, pick-and-place, document scanning, and other machine vision applications that require cost-effective mono, color, and multispectral imaging.

Tetra sensors are available in a 2k resolution with a 14 μm x 14 μm pixel size, or 4k resolution with a 7 μm x 7 μm pixel size at a max line rate of 128kHz aggregate. The mono models can be configured to output one, two, or four rows and the color models provide RGB and mono outputs. Using wafer level coated dichroic filters, the sensor also provides spectrally independent RGB and NIR outputs for multispectral imaging.

Based on a synchronized shutter design, Tetra provide low read noise and high dynamic range with true correlated double sampling (CDS). Each channel has its own exposure control, resulting in easy-to-perform white balancing.

The ceramic LCC package also offers high performance and high reliability over a wide range of operating temperatures. The sensor data ports have high signal integrity and simple interfacing for quick system integration.

Florian Julien, Director of the Machine Vision Team at Teledyne e2v said, “The sorting industry has started to upgrade its traditional technology from color to multispectral imaging. With its unique RGB + NIR capability, Tetra has been designed as the next generation technology to enhance quality and safety in food sorting.”

Please visit the product page or contact us for more information.

Notes to Editors:
For media enquiries, please contact:
Jessica.Broom@teledyne.com

Teledyne e2v is part of the Teledyne Imaging Group. Their innovations lead developments in healthcare, life sciences, space, transportation, defense and security and industrial markets. Teledyne e2v’s unique approach involves listening to the market and application challenges of customers and partnering with them to provide innovative standard, semi-custom or fully custom imaging solutions, bringing increased value to their systems.

For more information, visit imaging.teledyne-e2v.com

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers world-wide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5382ca84-0ca0-42f3-a353-f37006835df6

Tech Industry Veteran to Lead Expansion of Zoom’s APAC Business

SAN JOSE, Calif., June 28, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced Ricky Kapur will join the company as the Head of APAC, effective June 21. Reporting directly to Zoom’s Head of International Abe Smith, Kapur will define and lead the company’s go-to-market strategy for key APAC markets: Australia and New Zealand, ASEAN, China, Hong Kong SAR, India, Korea, and Taiwan — exclusive of Japan. Ricky will manage Zoom’s APAC business with supervision and alignment across all cross-functional roles.

Kapur comes to Zoom after five and a half years at Microsoft, where he was most recently Vice President of Sales and Marketing Operations for APAC. At Microsoft, he managed all segments, from SMB, Majors through Enterprise, and led a cross-functional team of sales, marketing, partner, and customer success professionals. Zoom is positioned for continued growth in APAC, and to capitalize on these new opportunities, it has expanded its leadership to lead the company through its next phase of expansion in the region.

“Zoom has scaled its operations and business impressively across APAC markets, announcing a Technology Center in India and a Research and Development Center in Singapore within the past year,” said Ricky Kapur, Head of APAC at Zoom. “I am excited to join a company that continues to redefine the way organizations and individuals connect, from breaking barriers for education and healthcare with virtual-learning and telehealth to becoming critical technology for enterprises as they quickly evolved and adapted to a hybrid working model.”

“We are thrilled to have Ricky Kapur lead our go-to-market strategy for all of APAC, a region where we are seeing accelerated growth,” said Abe Smith, Head of International at Zoom. “APAC is a critical region for Zoom, as we invest in infrastructure and expand the presence of our sales, marketing, and research and development teams to best enable organizations of all sizes with seamless and reliable video communications.”

About Ricky Kapur
Ricky Kapur is Head of APAC for Zoom, bringing over 25 years of experience to his role. Prior to joining Zoom, Kapur was Vice President of Sales and Marketing Operations at Microsoft APAC. In his role, he managed all segments, from SMB and Majors up to Enterprise and led a cross-functional team of Sales, Marketing, Partner and Customer Success and Operations professionals. Before joining Microsoft, Kapur served as Managing Director at Google where he was responsible for overseeing growth of Google Cloud Platform across APJ. Prior to that, Kapur held the position of Vice President, ASEAN Technology Sales at Oracle. He also worked at Siebel Systems, Unica Corporation, and Chordiant Software. Kapur is a chartered accountant from the Institute of Chartered Accountants in India and holds an MBA from the University of Melbourne.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Public Relations
Hayley Yap
APAC PR Lead
press@zoom.us

SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014.

In June 2019, Junshi Biosciences and Anwita Biosciences entered into a license agreement to develop and commercialize JS014 in the Greater China territories (including mainland China, Hong Kong, Macao, and Taiwan).

About JS014
JS014 is a novel recombinant IL-21 and anti human serum albumin (HAS) single domain nanobody fusion protein with a prolonged half-life. It is able to bind specifically to human IL-21R with high affinity and activate T-lymphocyte. The prolongation of half-life can expand the distribution of the drug and enhance the activity of tumor infiltrating lymphocytes in the tumor microenvironment, thereby improving the ability of the immune system to kill tumor cells.

Preclinical studies demonstrate that JS014 and JS001 (toripalimab) have strong synergistic antitumor effect.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) from the US FDA in February 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at a high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

 

BRIDGEWATER, N.J., June 25, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (SNCR) (the “Company” or “Synchronoss”), a global leader and innovator in cloud, messaging and digital products and platforms, today announced the pricing of an underwritten public offering of $125 million aggregate principal amount of 8.375% senior notes due 2026, including the exercise in full by the underwriters of the underwriters’ option to purchase an additional $5 million aggregate principal amount of senior notes. The offering is expected to close on or about June 30, 2021, subject to satisfaction of customary closing conditions.

Synchronoss and the senior notes both received a rating of BB- from Egan-Jones Ratings Company, an independent, unaffiliated rating agency. The Company has applied to list the senior notes on the Nasdaq Global Select Market under the symbol “SNCRL” and expects the notes to begin trading within 30 business days of the closing date of the offering, if approved.

All of the senior notes in the offering are being sold by Synchronoss. Synchronoss anticipates using the net proceeds from the offering, and from the offering of common stock and sale of Series B Preferred Stock (each as described below), to fully redeem all outstanding shares of Synchronoss’ Series A Convertible Participating Perpetual Preferred Stock and repay amounts outstanding under Synchronoss’ revolving credit facility.

B. Riley Securities, Inc. (“BRS”) is acting as the sole book-running manager for the offering. Northland Capital Markets, Aegis Capital Corp. and EF Hutton, division of Benchmark Investments, LLC are acting as lead managers for the offering.

Concurrently with the offering, the Company is offering, by means of a separate prospectus supplement, $100 million of shares of its common stock. In addition, B. Riley Principal Investments, LLC (“BRPI”), an affiliate of BRS, has entered into an agreement pursuant to which BRPI has agreed to purchase $75.0 million of the Company’s Series B Preferred Stock in a private transaction to be completed concurrently with the closing of the offering.

The senior notes described above are being offered by Synchronoss pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on August 28, 2020. A preliminary prospectus supplement relating to and describing the terms of the offering is filed with the SEC and is available on the SEC’s web site at www.sec.gov. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC. Copies of the final prospectus supplement (when available) and accompanying prospectus relating to these securities may also be obtained by sending a request to: B. Riley Securities, Inc., at 1300 North 17th Street, Suite 1300, Arlington, VA 22209 or by calling (703) 312‐9580 or by emailing prospectuses@brileyfin.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Synchronoss

Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the closing of the public offering and the anticipated use of the proceeds thereof. These forward-looking statements are subject to a number of risks, including the satisfaction of customary closing conditions related to the public offering and the risk factors set forth from time to time in Synchronoss’ SEC filings, including but not limited to the risks that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections (as applicable) of Synchronoss’ Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the period ended March 31, 2021, which are on file with the SEC and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Synchronoss’ other filings with the SEC, other unknown or unpredictable factors also could affect Synchronoss’ results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Synchronoss undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Media

Diane Rose
CCgroup
diane@ccgrouppr.com

Investors

Todd Kehrli/Joo-Hun Kim
MKR Investor Relations, Inc.
investor@synchronoss.com